AstraZeneca
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Clinical Trials
3.8k
Trial Phases
6 Phases
Drug Approvals
31
Drug Approvals
- Prev
- 1
- 2
- 3
- 4
- Next
Clinical Trials
Distribution across different clinical trial phases (2765 trials with phase data)• Click on a phase to view related trials
A Study to Investigate the Effect of AZD0780 on Metformin Pharmacokinetics in Healthy Adult Volunteers Aged 18 to 55 Years
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2025-10-14
- Last Posted Date
- 2025-10-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 14
- Registration Number
- NCT07216131
AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL
- Conditions
- Large B-cell Lymphoma
- Interventions
- Drug: R-mini-CHOP
- First Posted Date
- 2025-10-10
- Last Posted Date
- 2025-10-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 420
- Registration Number
- NCT07215585
- Locations
- 🇰🇷
Research Site, Seoul, South Korea
Understanding Non-small Cell Lung Cancer Patient Characteristics, Treatment Patterns and Outcomes
- Conditions
- Non-small Cell Lung Cancer
- First Posted Date
- 2025-10-10
- Last Posted Date
- 2025-10-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 800
- Registration Number
- NCT07215026
A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury.
- Conditions
- SepsisAcute Kidney Injury
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-10-10
- Last Posted Date
- 2025-10-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 124
- Registration Number
- NCT07215702
- Locations
- 🇬🇧
Research Site, London, United Kingdom
A Real-life Observational Study in Severe Eosinophilic Asthma Adult Participant Treated With Benralizumab sc Injection in Italy
- Conditions
- Severe Eosinophilic Asthma
- First Posted Date
- 2025-10-09
- Last Posted Date
- 2025-10-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 335
- Registration Number
- NCT07214753
- Locations
- 🇮🇹
AZIENDA ULSS 6 EUGANEA_OSPEDALE DI CITTADELLA U.O.C. di Pneumologia, Cittadella, Padova, Italy
🇮🇹PRESIDIO OSPEDALIERO SANTA MARIA DELLA SPERANZA U.O.C. Medicina Interna, Battipaglia, Salerno, Italy
🇮🇹OSPEDALE MARIA S.S. DELLO SPLENDORE U.O.S.D. Allergologia Territoriale presidio ospedaliero Giulianova, Giulianova, Teramo, Italy
- Prev
- 1
- 2
- 3
- 4
- 5
- 668
- Next
News
Takeda Expands AI Drug Discovery Partnership with Nabla Bio in $1B+ Deal
Takeda Pharmaceutical has signed a second multi-year AI partnership with Nabla Bio, potentially worth over $1 billion including milestone payments, to accelerate early-stage drug discovery using artificial intelligence.
Activist Investor Shah Capital Calls for Novavax Sale Amid COVID Vaccine Market Share Struggles
Shah Capital, Novavax's second-largest shareholder with a 7.2% stake, has urged the company's board to pursue a sale, citing three consecutive years of poor COVID-19 vaccine performance.
Ona Therapeutics Appoints ADC Development Veteran Dr. Antoine Yver as Board Chair to Advance Breast Cancer Pipeline
Ona Therapeutics has appointed Dr. Antoine Yver, a veteran with over 35 years of oncology drug development experience, as Chair of its Board of Directors to guide the company's transition to clinical-stage operations.
Innate Pharma Advances Lacutamab Toward Accelerated Approval for Rare T-Cell Lymphomas
Innate Pharma will host an investor event on October 28, 2025, to discuss lacutamab's path to potential accelerated approval in Sézary syndrome based on Phase 2 TELLOMAK trial data.
New Report Analyzes 1,775 Clinical-Stage Pharma Partnerships from 2020-2025
ResearchAndMarkets.com released a comprehensive report analyzing 1,775 clinical-stage partnering deals in pharma and biotech from 2020-2025, providing detailed financial terms and strategic insights.
Eli Lilly and AstraZeneca Emerge as Leading Candidates for Next Trump Administration Drug Pricing Deal
Wall Street analysts predict Eli Lilly and AstraZeneca are the most likely pharmaceutical companies to strike the next drug pricing deal with the Trump administration following Pfizer's September 29 agreement.
Arthrosi Raises $153M to Advance Next-Generation Gout Therapy Through Phase III Trials
Arthrosi Therapeutics completed a $153 million Series E funding round led by Prime Eight Capital to advance pozdeutinurad (AR882) through Phase III trials for gout treatment.
Algen Biotechnologies Partners with AstraZeneca in $555M AI-Driven Drug Discovery Deal for Immunology Targets
Algen Biotechnologies announced a multi-target partnership with AstraZeneca worth up to $555 million to accelerate discovery of novel therapeutic targets in immunology using AI-powered drug discovery.
Amgen's Repatha Demonstrates Long-Term Cardiovascular Benefits in Phase III VESALIUS-CV Trial
Amgen's Phase III VESALIUS-CV trial met both primary endpoints, demonstrating that Repatha significantly reduces major adverse cardiovascular events in high-risk patients without prior heart attack or stroke.
Thermo Fisher Scientific Partners with AstraZeneca BioVentureHub for Collaborative R&D Innovation
Thermo Fisher Scientific's PPD clinical research business has established a new R&D partnership with AstraZeneca BioVentureHub in Gothenburg, Sweden, focusing on collaborative innovation in life sciences.